Trial Profile
Multicenter, Open, Non-Randomised Phase III Clinical Study of Efficacy and Safety of Insulin Glulisine (HMR1964) Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus Using Also Insulin Glargine During 26 Weeks of Therapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin glulisine (Primary) ; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 03 Nov 2007 New trial record.